Apogee Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 91
- Market Cap
- $2.6B
- Introduction
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Apogee Therapeutics to host virtual R&D Day on Dec 2, 2024, discussing APG777's potential in AD and the role of combinations in I&I treatments.
Paragon spinout joins hunt for new type of cancer immunotherapy
Crescent Biopharma, a Paragon Therapeutics spinout, merges with GlycoMimetics, raising $200M to advance cancer immunotherapy targeting PD-1 and VEGF. Crescent aims to improve upon standard treatments like Keytruda, with initial data expected in 2026. The merger is set to close in Q2 2025.
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030
Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.
Chief Medical Officer Dambkowski Carl sold $316,969 worth of shares (6,665 units at $47.56
Apogee Therapeutics appoints Lisa Bollinger, MD, to its board of directors. Dr. Bollinger, formerly of Merck, brings over 30 years of drug development experience.
© Copyright 2025. All Rights Reserved by MedPath